$BMRN
BIOMARIN PHARMACEUTICAL INC

2015 Q2 Form 10-Q Financial Statement

#000156459015006130 Filed on August 05, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2014 Q4 2014 Q2
Revenue $250.1M $230.1M $191.8M
YoY Change 30.41% 56.64% 40.18%
Cost Of Revenue $38.10M $38.30M $31.21M
YoY Change 22.08% 55.69% 38.3%
Gross Profit $212.1M $191.7M $160.6M
YoY Change 32.09% 56.75% 40.56%
Gross Profit Margin 84.81% 83.31% 83.73%
Selling, General & Admin $100.0M $103.1M $68.09M
YoY Change 46.87% 45.21% 34.41%
% of Gross Profit 47.15% 53.78% 42.4%
Research & Development $157.9M $142.1M $107.7M
YoY Change 46.61% 46.04% 25.73%
% of Gross Profit 74.45% 74.13% 67.07%
Depreciation & Amortization $12.30M $6.000M $10.40M
YoY Change 18.27% -500.0% 10.64%
% of Gross Profit 5.8% 3.13% 6.48%
Operating Expenses $260.4M $253.5M $175.8M
YoY Change 48.13% 40.52% 28.96%
Operating Profit -$64.24M -$61.80M -$18.88M
YoY Change 240.22% 6.37% -5.83%
Interest Expense $10.00M -$4.300M $9.221M
YoY Change 8.47% -458.33% 1429.19%
% of Operating Profit
Other Income/Expense, Net -$9.100M $300.0K -$100.0K
YoY Change 9000.0% -50.0% 0.0%
Pretax Income -$82.54M -$65.70M -$27.73M
YoY Change 197.69% 10.61% 36.65%
Income Tax -$554.0K $4.100M $5.774M
% Of Pretax Income
Net Earnings -$81.99M -$69.80M -$33.50M
YoY Change 144.73% 12.58% 55.58%
Net Earnings / Revenue -32.78% -30.33% -17.47%
Basic Earnings Per Share -$0.51 -$0.23
Diluted Earnings Per Share -$0.51 -$471.0K -$0.23
COMMON SHARES
Basic Shares Outstanding 160.4M 147.5M shares 146.1M shares
Diluted Shares Outstanding 160.4M 146.4M shares

Balance Sheet

Concept 2015 Q2 2014 Q4 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $681.6M $945.2M $836.6M
YoY Change -18.53% 20.45% 108.84%
Cash & Equivalents $440.7M $875.5M $584.7M
Short-Term Investments $240.9M $69.70M $251.9M
Other Short-Term Assets $108.8M $108.5M $37.27M
YoY Change 191.94% 160.21% 11.16%
Inventory $237.5M $199.5M $193.5M
Prepaid Expenses $36.17M $35.39M
Receivables $186.1M $144.5M $122.3M
Other Receivables $0.00 $9.700M $0.00
Total Short-Term Assets $1.214B $1.398B $1.220B
YoY Change -0.52% 22.88% 69.26%
LONG-TERM ASSETS
Property, Plant & Equipment $568.1M $523.5M $469.9M
YoY Change 20.91% 63.95% 66.62%
Goodwill $54.26M $54.26M
YoY Change 0.0% -1.3%
Intangibles $156.6M $163.0M
YoY Change -4.03% -3.2%
Long-Term Investments $509.6M $97.90M $244.6M
YoY Change 108.34% -63.54% 95.84%
Other Assets $230.8M $54.56M $46.56M
YoY Change 395.68% -65.07% 212.85%
Total Long-Term Assets $2.435B $1.078B $1.125B
YoY Change 116.34% -2.61% 27.81%
TOTAL ASSETS
Total Short-Term Assets $1.214B $1.398B $1.220B
Total Long-Term Assets $2.435B $1.078B $1.125B
Total Assets $3.649B $2.475B $2.346B
YoY Change 55.55% 10.31% 46.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $26.14M $32.78M $21.71M
YoY Change 20.37% -11.15% 33.54%
Accrued Expenses $109.6M $98.49M $79.34M
YoY Change 38.19% 68.62% 52.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $347.7M $235.7M $166.7M
YoY Change 108.55% 28.63% 17.21%
LONG-TERM LIABILITIES
Long-Term Debt $661.5M $642.9M $650.9M
YoY Change 1.63% -1.94% 492.81%
Other Long-Term Liabilities $89.30M $30.08M $25.66M
YoY Change 248.04% -9.93% -16.58%
Total Long-Term Liabilities $750.8M $30.08M $25.66M
YoY Change 2826.18% -9.93% -16.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $347.7M $235.7M $166.7M
Total Long-Term Liabilities $750.8M $30.08M $25.66M
Total Liabilities $1.292B $947.5M $883.7M
YoY Change 46.17% 4.92% 157.45%
SHAREHOLDERS EQUITY
Retained Earnings -$849.8M -$787.4M
YoY Change 18.72% 31.06%
Common Stock $2.360B $2.250B
YoY Change 14.6% 20.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.357B $1.528B $1.462B
YoY Change
Total Liabilities & Shareholders Equity $3.649B $2.475B $2.346B
YoY Change 55.55% 10.31% 46.47%

Cashflow Statement

Concept 2015 Q2 2014 Q4 2014 Q2
OPERATING ACTIVITIES
Net Income -$81.99M -$69.80M -$33.50M
YoY Change 144.73% 12.58% 55.58%
Depreciation, Depletion And Amortization $12.30M $6.000M $10.40M
YoY Change 18.27% -500.0% 10.64%
Cash From Operating Activities -$13.00M -$25.40M -$11.90M
YoY Change 9.24% 182.22% 75.0%
INVESTING ACTIVITIES
Capital Expenditures -$35.50M -$27.80M $20.00M
YoY Change -277.5% -6.71% -292.31%
Acquisitions
YoY Change
Other Investing Activities -$409.8M $490.5M $100.0K
YoY Change -409900.0% -277.2% -99.56%
Cash From Investing Activities -$445.2M $462.7M -$41.00M
YoY Change 985.85% -250.96% -436.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.400M 43.00M -3.200M
YoY Change -25.0% -93.9% -120.51%
NET CHANGE
Cash From Operating Activities -13.00M -25.40M -11.90M
Cash From Investing Activities -445.2M 462.7M -41.00M
Cash From Financing Activities -2.400M 43.00M -3.200M
Net Change In Cash -460.6M 480.3M -56.10M
YoY Change 721.03% 23.31% -367.14%
FREE CASH FLOW
Cash From Operating Activities -$13.00M -$25.40M -$11.90M
Capital Expenditures -$35.50M -$27.80M $20.00M
Free Cash Flow $22.50M $2.400M -$31.90M
YoY Change -170.53% -88.46% -986.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
160406000
CY2015Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1023000
CY2014Q2 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
674000
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
163000
CY2015Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-9121000
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2014Q2 us-gaap Costs And Expenses
CostsAndExpenses
210669000
CY2015Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-204000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18882000
CY2014Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-539000
CY2014Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1735000
CY2015Q2 us-gaap Interest Expense
InterestExpense
10002000
CY2014Q2 us-gaap Interest Expense
InterestExpense
9221000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-64240000
CY2015Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
47109000
CY2015Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
123732000
CY2015Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
847238000
CY2015Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
970970000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
752405000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
228889000
us-gaap Depreciation
Depreciation
23700000
CY2014Q2 us-gaap Depreciation
Depreciation
10400000
CY2015Q2 bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
3700000
CY2015Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
25798000
CY2015Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
140959000
CY2015Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
70775000
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-82544000
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-555000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-81989000
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
160406000
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-93347000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
29579000
us-gaap Paid In Kind Interest
PaidInKindInterest
14080000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-941000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
132920000
us-gaap Origination Of Notes Receivable From Related Parties
OriginationOfNotesReceivableFromRelatedParties
3326000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
538392000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-150802000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
79288000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
154200000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
119666000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
729263000
us-gaap Share Based Compensation
ShareBasedCompensation
54396000
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
9265000
us-gaap Gain Loss On Sale Of Equity Investments
GainLossOnSaleOfEquityInvestments
3022000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
12802000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-14951000
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
385000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
10203000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
14606000
us-gaap Other Noncash Income
OtherNoncashIncome
-721000
us-gaap Other Noncash Income
OtherNoncashIncome
-1876000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
37587000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
38434000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-2211000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-497000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-33633000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
7070000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
1500000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1196069000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-78879000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
45427000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
28102000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
19566000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
6694000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
888257000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
117464000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
385000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
331000
bmrn Payment Of Contingent Consideration Of Acquisitions
PaymentOfContingentConsiderationOfAcquisitions
4691000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-2063000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-707000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
912440000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
133805000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-391000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-1032000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-434822000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
15936000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
568781000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
584717000
us-gaap Interest Paid Net
InterestPaidNet
5133000
us-gaap Interest Paid Net
InterestPaidNet
4855000
us-gaap Income Taxes Paid
IncomeTaxesPaid
13814000
us-gaap Income Taxes Paid
IncomeTaxesPaid
13091000
bmrn Stockbased Compensation Capitalized
StockbasedCompensationCapitalized
5492000
bmrn Stockbased Compensation Capitalized
StockbasedCompensationCapitalized
3909000
bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
7316000
bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
5348000
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease
-6911000
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease
-5978000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
8133000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
16482000
us-gaap Escrow Deposit Disbursements Related To Property Acquisition1
EscrowDepositDisbursementsRelatedToPropertyAcquisition1
116500000
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1) NATURE OF OPERATIONS AND BUSINESS RISKS</p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">BioMarin Pharmaceutical Inc. (the Company or BioMarin), a Delaware corporation, develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. BioMarin selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company&#8217;s product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. The Company&#8217;s approved products are Vimizim (elosulfase alfa), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through June 30, 2015, the Company had accumulated losses of approximately $999.3 million. The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents, short-term and long-term investments, and to the extent necessary, through proceeds from equity or debt financings, loans and collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks, including: the financial performance of Vimizim, Naglazyme, Kuvan, Aldurazyme and Firdapse; the potential need for additional financings; the Company&#8217;s ability to successfully commercialize its approved product candidates; the uncertainty of the Company&#8217;s research and development (R&amp;D) efforts resulting in future successful commercial products; the Company&#8217;s ability to successfully obtain regulatory approval for new products; significant competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; and possible restrictions on reimbursement from governmental agencies and healthcare organizations, as well as other changes in the health care industry. </p></div>
us-gaap Basis Of Accounting
BasisOfAccounting
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2) BASIS OF PRESENTATION</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (U.S. GAAP) for complete financial statements. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2014 included in the Company&#8217;s Annual Report on Form 10-K.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management&#8217;s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The results of operations for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending December&#160;31, 2015.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated events and transactions subsequent to the balance sheet date. Based on this evaluation, the Company is not aware of any events or transactions that occurred subsequent to the balance sheet date but prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</p></div>
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(4) RECENT ACCOUNTING PRONOUNCEMENTS</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Except as described below, there have been no new accounting pronouncements or changes to accounting pronouncements during the six months ended June 30, 2015, as compared to the recent accounting pronouncements described in Note 4 of the Company&#8217;s Annual Report on Form 10-K for the year-ended December&#160;31, 2014, that are of significance or potential significance to the Company.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2015, the <font style="color:#000000;">Financial Accounting Standards Board (</font>FASB) deferred the effective date for Accounting Standards Update (ASU) No. 2014-09 (ASU 2014-09),<font style="font-style:italic;"> Revenue from Contracts with Customers,</font> by one year. ASU 2014-09 will supersede the revenue recognition requirements in<font style="font-style:italic;"> Revenue Recognition (Topic 605)</font> and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for annual reporting periods beginning after December&#160;15, 2017, including interim periods within that reporting period, which for the Company is January&#160;1, 2018. Early adoption is not permitted.&#160;The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application in retained earnings. The Company is currently evaluating the potential impact the adoption of ASU 2014-09 will have on its consolidated financial statements and has not yet selected a transition method.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2015, the FASB issued ASU 2015-03, <font style="font-style:italic;">Interest&#8211;Imputation of Interest (Subtopic 835-30)</font>, which changes the presentation of debt issuance costs in financial statements. ASU 2015-03 requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. It is effective for annual reporting periods beginning after December&#160;15,&#160;2016, which for the Company is January 1, 2017. Early adoption is permitted. The new guidance will be applied retrospectively to each prior period presented. The adoption of this standard will not have an impact on the Company&#8217;s results of operations and will result in a reclassification of the balance of deferred offering costs at the time of adoption. If the standard were adopted as of June 30, 2015, the reclassification would approximate $13.4 million. </p></div>
CY2014Q2 us-gaap Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares
EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares
-507000
bmrn Number Of Products Approved
NumberOfProductsApproved
5
CY2015Q2 bmrn Reclassification Of Deferred Offering Costs
ReclassificationOfDeferredOfferingCosts
13400000
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9775000
CY2015Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
93.25
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
888300000
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-81989000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33502000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-149490000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-71617000
us-gaap Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares
EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares
-746000
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-81989000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-34009000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-149490000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-72363000
CY2014Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
231000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
231000
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22237000
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24401000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22116000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24555000
CY2015Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
751198000
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
209000
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
891000
CY2015Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
750516000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
167830000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
74000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
342000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
167562000
bmrn Number Of Investments In Marketable Equity Securities
NumberOfInvestmentsInMarketableEquitySecurities
2
CY2015Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
30100000
CY2014Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
30800000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
24700000
CY2014 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
18300000
CY2015Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
240889000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
69706000
CY2015Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
509627000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
97856000
CY2015Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
750516000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
167562000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
148134000
CY2014Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
123365000
CY2014Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
74430000
CY2014Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
197795000
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
41217000
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
820523000
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
252472000
CY2015Q2 us-gaap Depreciation
Depreciation
12300000
us-gaap Depreciation
Depreciation
20000000
CY2014Q2 bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
2400000
CY2014Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
22488000
CY2014Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
114393000
CY2014Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
62571000
CY2015Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
36167000
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
35390000
CY2015Q2 us-gaap Derivative Assets Current
DerivativeAssetsCurrent
16003000
CY2014Q4 us-gaap Derivative Assets Current
DerivativeAssetsCurrent
10513000
CY2014Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
46946000
CY2015Q2 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
7158000
CY2014Q4 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
2354000
CY2014Q4 bmrn Convertible Promissory Note Conversion Option
ConvertiblePromissoryNoteConversionOption
2386000
CY2015Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
11333000
CY2014Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
9733000
CY2015Q2 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
6897000
CY2014Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
4513000
CY2015Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
5324000
CY2014Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
12021000
CY2015Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
10085000
CY2014Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
11763000
CY2015Q2 us-gaap Investments
Investments
30093000
CY2014Q4 us-gaap Investments
Investments
30811000
CY2015Q2 us-gaap Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
5953000
CY2014Q4 us-gaap Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
5387000
CY2015Q2 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
6829000
CY2014Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
6338000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
26135000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
32779000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
109633000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
98490000
CY2015Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
40618000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
45479000
CY2015Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
15999000
CY2014Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
12540000
CY2015Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
29494000
CY2014Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
14859000
CY2015Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
9518000
CY2014Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
9050000
CY2015Q2 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
6358000
CY2014Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
5479000
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9480000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8244000
CY2015Q2 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
9095000
CY2014Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
4924000
CY2015Q2 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
1385531000
CY2014Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
1079792000
CY2015Q2 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
21956000
CY2015Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
5137000
CY2014Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
15900000
CY2014Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
12000
us-gaap Derivative Instruments Gain Loss Recognized In Other Comprehensive Income Effective Portion Net
DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
17100000
CY2014 us-gaap Derivative Instruments Gain Loss Recognized In Other Comprehensive Income Effective Portion Net
DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
15900000
CY2014Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
3765000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
69000
us-gaap Asset Retirement Obligation Liabilities Incurred
AssetRetirementObligationLiabilitiesIncurred
112000
CY2015Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
3946000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
688270
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
56.46
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29509000
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17250000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
52201000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33555000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
5500000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
3900000
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
54497000
CY2015Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
7000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-2457000
CY2015Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
3022000
CY2015Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-5479000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
-2711000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
2740000
CY2015Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax
5158000
CY2015Q2 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
-7869000
CY2015Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
1093000
CY2015Q2 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-13341000
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
41156000
CY2015Q1 bmrn Accumulated Other Comprehensive Income Loss Tax
AccumulatedOtherComprehensiveIncomeLossTax
10678000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-890000
CY2015Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
-1983000
CY2015Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-1983000
CY2015Q2 bmrn Accumulated Other Comprehensive Income Loss Tax
AccumulatedOtherComprehensiveIncomeLossTax
8695000
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
43819000
CY2015Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
7000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1567000
CY2015Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
1929000
CY2015Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-3496000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-2711000
CY2015Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
5158000
CY2015Q2 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
-7869000
CY2015Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-11358000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
33984000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
2000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
9024000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
3022000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
6002000
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
11065000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax
9897000
us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
1168000
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
7172000
CY2014Q4 bmrn Accumulated Other Comprehensive Income Loss Tax
AccumulatedOtherComprehensiveIncomeLossTax
6518000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
3270000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
1093000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
2177000
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
2177000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5754000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
1929000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
3825000
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
11065000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
9897000
us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
1168000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4995000
CY2014Q1 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
11302000
CY2014Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
-38000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
2196000
CY2014Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
2196000
CY2014Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax
-710000
CY2014Q2 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
2030000
CY2014Q2 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
4188000
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
15490000
CY2014Q1 bmrn Accumulated Other Comprehensive Income Loss Tax
AccumulatedOtherComprehensiveIncomeLossTax
4027000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
790000
CY2014Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
790000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
988000
CY2014Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax
256000
CY2014Q2 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax
732000
CY2014Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
1522000
CY2014Q2 bmrn Accumulated Other Comprehensive Income Loss Tax
AccumulatedOtherComprehensiveIncomeLossTax
5549000
CY2014Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
7275000
CY2014Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-38000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1406000
CY2014Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1406000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
1752000
CY2014Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-454000
CY2014Q2 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
1298000
CY2014Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2666000
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
9941000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
7756000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
-33000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
4441000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
4441000
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
4923000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax
-1597000
us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
3326000
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
7734000
CY2013Q4 bmrn Accumulated Other Comprehensive Income Loss Tax
AccumulatedOtherComprehensiveIncomeLossTax
2738000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
1612000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
1612000
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
1775000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax
576000
us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax
1199000
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
2811000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5018000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-33000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2829000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2829000
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
3148000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-1021000
us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
2127000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4923000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
bmrn Contingent Payments Upon Achievement Of Certain Regulatory And Licensing Milestones
ContingentPaymentsUponAchievementOfCertainRegulatoryAndLicensingMilestones
727900000
CY2015Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
128700000
CY2015Q2 us-gaap Purchase Obligation
PurchaseObligation
72600000

Files In Submission

Name View Source Status
0001564590-15-006130-index-headers.html Edgar Link pending
0001564590-15-006130-index.html Edgar Link pending
0001564590-15-006130.txt Edgar Link pending
0001564590-15-006130-xbrl.zip Edgar Link pending
bmrn-10q_20150630.htm Edgar Link pending
bmrn-20150630.xml Edgar Link completed
bmrn-20150630.xsd Edgar Link pending
bmrn-20150630_cal.xml Edgar Link unprocessable
bmrn-20150630_def.xml Edgar Link unprocessable
bmrn-20150630_lab.xml Edgar Link unprocessable
bmrn-20150630_pre.xml Edgar Link unprocessable
bmrn-ex31_6.htm Edgar Link pending
bmrn-ex31_7.htm Edgar Link pending
bmrn-ex32_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending